Maravai LifeSciences Holdings Inc (MRVI)

Maravai LifeSciences To Attend The Jefferies Global Healthcare ConferenceMay 18, 2026 4:00 PM
Business Wire Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company will participate in the following investor conference in June. On June 4, 2026, at 12:50 p.m. Eastern Time, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City, NY. A live webcast of the fireside chat will be on the Maravai LifeSciences Investor Relations website, under News & Events, IR Calendar. An archived replay of the webcast will also be available on the website following the event. About Maravai Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies. For more information about Maravai LifeSciences, visit www.maravai.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260518944378/en/ Investor Contact:
Deb Hart
Maravai LifeSciences
+1 858-988-5917
ir@maravai.com Original: Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference

Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026April 20, 2026 4:05 PM
Business Wire
Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2026 financial and operating results after the market close on Thursday, May 7, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.


To participate in the conference call by telephone, dial 1-800-343-5172 or 1-203-518-9856 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com.


About Maravai


Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260420078369/en/
Deb Hart

Maravai LifeSciences

+ 1 858-988-5917

ir@maravai.com


Original: Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026February 9, 2026 5:05 PM
Business Wire
Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2025 financial and operating results after the market close on Wednesday, February 25, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.


To participate in the conference call by telephone, dial 1-800-343-4136 or 1-203-518-9843 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com.


About Maravai


Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260209610603/en/
Deb Hart

Maravai LifeSciences

+ 1 858-988-5917

ir@maravai.com


Original: Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026

MRVI No 2 on the Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Maravai LifeSciences stock price target raised to $50 from $31 at Stifel Nicolaus
7:24 am ET March 3, 2021 (MarketWatch)

Maravai LifeSciences shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued FY21 EPS and sales guidance above estimates.

Mar 3, 2021 7:35a ETBenzinga Stock Analysis

Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enables the development of drug therapies, diagnostics, vaccines and support research on human diseases. The Company's segments include Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products used in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Its Biologics Safety Testing segment sells specialized analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. The Company's Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry.